SUNESIS PHARMACEUTICALS INC's ticker is SNSS and the CUSIP is 867328700. A total of 41 filers reported holding SUNESIS PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $5,000 | +150.0% | 21,287 | +285.9% | 0.00% | – |
| Q1 2020 | $2,000 | -60.0% | 5,516 | -62.6% | 0.00% | – |
| Q4 2019 | $5,000 | -79.2% | 14,758 | -55.9% | 0.00% | – |
| Q3 2019 | $24,000 | +33.3% | 33,494 | +37.0% | 0.00% | – |
| Q2 2019 | $18,000 | -56.1% | 24,454 | -28.1% | 0.00% | – |
| Q1 2019 | $41,000 | +173.3% | 33,989 | -12.1% | 0.00% | – |
| Q4 2018 | $15,000 | -28.6% | 38,687 | +265.3% | 0.00% | – |
| Q3 2018 | $21,000 | -58.0% | 10,591 | -55.1% | 0.00% | – |
| Q2 2018 | $50,000 | -31.5% | 23,577 | -12.1% | 0.00% | – |
| Q1 2018 | $73,000 | -11.0% | 26,811 | +19.8% | 0.00% | – |
| Q4 2017 | $82,000 | +57.7% | 22,371 | -16.6% | 0.00% | – |
| Q3 2017 | $52,000 | -36.6% | 26,818 | -11.6% | 0.00% | – |
| Q2 2017 | $82,000 | -70.5% | 30,351 | -55.5% | 0.00% | – |
| Q1 2017 | $278,000 | +892.9% | 68,160 | +768.1% | 0.00% | – |
| Q4 2016 | $28,000 | +27.3% | 7,852 | +57.9% | 0.00% | – |
| Q3 2016 | $22,000 | – | 4,972 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 7,600,000 | $9,234,000 | 7.03% |
| Samsara BioCapital, LLC | 3,750,000 | $4,556,000 | 3.58% |
| CAXTON CORP | 277,245 | $337,000 | 0.31% |
| BVF INC/IL | 2,287,860 | $2,780,000 | 0.31% |
| Eventide Asset Management | 5,965,455 | $7,248,000 | 0.25% |
| Telemetry Investments, L.L.C. | 197,564 | $240,000 | 0.12% |
| NEA Management Company, LLC | 1,298,274 | $1,584,000 | 0.08% |
| RP Management, LLC | 129,517 | $158,000 | 0.08% |
| Palo Alto Investors LP | 1,162,473 | $1,412,000 | 0.06% |
| Fosun International Ltd | 725,000 | $863,000 | 0.06% |